


3-Hydroxyphenylacetic acid

Chemical Properties

CAS No. :	621-37-4
Formula:	C ₈ H ₈ O ₃
Molecular Weight:	152.15
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	3-Hydroxyphenylacetic acid is a rutin metabolite and an antioxidant. It has a protective biological activity in human. It is a substrate of enzyme 4-hydroxyphenylacetate 3-monooxygenase [EC 1.14.13.3] in the pathway tyrosine metabolism. 3-Hydroxyphenylacetic acid is found to be associated with phenylketonuria, which is an inborn error of metabolism.
Targets(IC50)	Apoptosis, Ferroptosis, Glutathione Peroxidase, Nrf2, Endogenous Metabolite, Dehydrogenase, ROS

Solubility Information

Solubility	DMSO: 55 mg/mL (361.49 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (13.14 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	6.5725 mL	32.8623 mL	65.7246 mL
5 mM	1.3145 mL	6.5725 mL	13.1449 mL
10 mM	0.6572 mL	3.2862 mL	6.5725 mL
50 mM	0.1314 mL	0.6572 mL	1.3145 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Young S N , Davis B A , Gauthier S . Precursors and metabolites of phenylethylamine, m and p-tyramine and tryptamine in human lumbar and cisternal cerebrospinal fluid.[J]. Journal of Neurology Neurosurgery & Psychiatry, 1982, 45(7):633-9.

Davis B A , Durden D A , Boulton A A . Plasma concentrations of p- and m-hydroxyphenylacetic acid and phenylacetic acid in humans: gas chromatographic--high-resolution mass spectrometric analysis.[J]. J Chromatogr, 1982, 230(2):219-230.

Davis B A , Boulton A A . Longitudinal urinary excretion of some "trace" acids in a human male[J]. Journal of Chromatography, 1981, 222(2):161-169.

Nahmias C , Wahl L M , Amano S , et al. Chirakal R. Equilibration of 6-[18F]fluoro-L-m-tyrosine between plasma and erythrocytes[J]. Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine, 2000, 41(10):1636.

Baba S , Furuta T , Horie M , et al. Studies on drug metabolism by use of isotopes XXVI: Determination of urinary metabolites of rutin in humans[J]. Journal of Pharmaceutical Sciences, 2010, 70(7):780-782.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481